FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to haematology, and concerns correction of granulocytopoiesis depression in cytostatic action. It is ensured by daily single introduction of recombinant human granulocytic colony-stimulating factor (G-CSF) in a dose 100 mkg/kg within 5 days that is preceded with introduction of a cytostatic agent. Herewith, 30 minutes prior to introduction of the cytostatic agent, reserpine dosed 2 mg/kg is introduced.
EFFECT: method provides effective correction of granulocytopoiesis and reduced by-effects of prolonged introduction of G-CSF owing to ability of reserpine introduced in the developed dose and the related schedule to potentiate effect of G-CSF.
9 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DETERMINING EFFICACY OF HAEMOSTIMULATORS IN CYTOSTATIC MYELOSUPPRESSION | 2009 |
|
RU2421720C2 |
| METHOD OF MYELOPOIESIS STIMULATION | 2008 |
|
RU2366452C1 |
| METHOD OF GRANULOCYTOPENIA-STIMULATING EFFECT EVALUATION FOR PHARMACOLOGICAL SUBSTANCES | 2006 |
|
RU2332667C1 |
| MEDICATION PREVENTING DEVELOPMENT OF DEPRESSION OF HEMATOPOIESIS ERYTHROID LINEAGE IN CASE OF CYTOSTATIC MYELO DEPRESSIONS | 2007 |
|
RU2351333C1 |
| METHOD OF MYELOPOIESIS STIMULATION | 2007 |
|
RU2336899C1 |
| MEDICINAL AGENT STIMULATING ERYTHROIDE HEMOPOIESIS GERM AT CYTOSTATIC MYELODEPRESSION STATES | 1992 |
|
RU2061475C1 |
| MEDICINAL AGENT STIMULATING ERYTHROID AND GRANULOCYTE ERYTHROPOIESIS STEMS AT CYTOSTATIC MYELODEPRESSIONS | 1993 |
|
RU2083201C1 |
| DRUG STIMULATING GRANULOCYTE HEMOPOIESIS GRAFT IN CYTOSTATIC MYELODEPRESSION | 1999 |
|
RU2157688C1 |
| AGENT INTENSIFYING ACTION OF BIOLOGICALLY ACTIVE SUBSTANCES AND DRUGS | 2009 |
|
RU2421239C1 |
| MEDICINE CAPABLE OF SELECTIVELY STIMULATING GRANULO-MONOCYTOPOIESIS IN CASE OF HYPOPLASIA OF MEDULLARY HEMOPOIESIS TRIGGERED BY CYTOSTATIC | 1988 |
|
RU2020936C1 |
